Joseph Bailey, MD
Internal Medicine · Crestview Hills, KYNPI 1144510231
Payments from drug & device makers
Across 121 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$517
- GSK$147
- AstraZeneca$146
- Pfizer$142
- Novo Nordisk$140
- Merck$122
- plus $730 from 22 others
What the payments were for
- Food & beverage$1,938100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $517 |
| GSK | 10 | $147 |
| AstraZeneca | 6 | $146 |
| Pfizer | 9 | $142 |
| Novo Nordisk | 9 | $140 |
| Merck | 14 | $122 |
| Amgen | 6 | $106 |
| Johnson & Johnson | 7 | $101 |
| Boehringer Ingelheim | 4 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $71 |
| Lilly USA, LLC | 3 | $44 |
| Biohaven Pharmaceuticals, Inc. | 3 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Cranial Technologies, Inc | 2 | $32 |
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
| Almatica Pharma LLC | 1 | $23 |
| Corcept Therapeutics | 1 | $20 |
| Bayer | 1 | $20 |
| Abbott | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Circassia Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Vanda Pharmaceuticals Inc. | 1 | $12 |
| Sobi, Inc | 1 | $12 |
| Dynavax Technologies Corporation | 1 | $7 |
How this compares
$1,944 in reported general payments places this provider in the 75th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 53 | $62,020 |
| FarxigaDapagliflozin Propanediol | 33 | $35,191 |
| MounjaroTirzepatide | 20 | $34,656 |
| XareltoRivaroxaban | 18 | $29,092 |
| OzempicSemaglutide | 22 | $28,778 |
| JardianceEmpagliflozin | 18 | $28,000 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $24,391 |
| JanuviaSitagliptin Phosphate | 11 | $17,511 |
| MyrbetriqMirabegron | 24 | $13,582 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $10,276 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $10,009 |
| Novolog FlexpenInsulin Aspart | 20 | $5,054 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $4,119 |
| Atorvastatin Calcium | 440 | $3,051 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 78 | $2,720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $142 | $62,02053 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta | $147 | $44,67651 claims |
| AstraZenecaFarxiga | $146 | $35,19133 claims |
| Lilly USA, LLCMounjaro | $44 | $34,65620 claims |
| Johnson & JohnsonXarelto | $101 | $29,09218 claims |
| Novo NordiskOzempic | $140 | $28,77822 claims |
| Boehringer IngelheimJardiance | $73 | $28,00018 claims |
| MerckJanuvia | $122 | $17,51111 claims |
| AbbVieSynthroid | $517 | $79018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Crestview Hills
- Barry WendtCrestview Hills$14K
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.